International Journal of Cardiology
Volume 129, Issue 3 , Pages 318-324 , 13 October 2008

Carcinoid heart disease

  • B.I. Gustafsson

      Affiliations

    • Department of Gastroenterological Surgery, Yale University School of Medicine New Haven, CT06520-8062, USA
    • Department of Gastroenterology, St Olavs Hospital HF, Trondheim University Hospital, N-7006 Trondheim, Norway
    • Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, N-7006 Trondheim, Norway
    • ,
  • O. Hauso

      Affiliations

    • Department of Gastroenterological Surgery, Yale University School of Medicine New Haven, CT06520-8062, USA
    • Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, N-7006 Trondheim, Norway
    • ,
  • I. Drozdov

      Affiliations

    • Department of Gastroenterological Surgery, Yale University School of Medicine New Haven, CT06520-8062, USA
    • ,
  • M. Kidd

      Affiliations

    • Department of Gastroenterological Surgery, Yale University School of Medicine New Haven, CT06520-8062, USA
    • ,
  • I.M. Modlin

      Affiliations

    • Department of Gastroenterological Surgery, Yale University School of Medicine New Haven, CT06520-8062, USA
    • Corresponding Author InformationCorresponding author. Department of Gastroenterological Surgery, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208062, New Haven, Connecticut 06520-8062, USA. Tel.: +1 203 785 5429; fax: +1 203 737 4067.

Received 5 December 2007 ,Accepted 9 February 2008.

References 

  1. Scholte A. Ein Fall von Angioma teleangieactaticum Cutis mit chronischer Endocarditis und malignem Dünndarmscarcinoid. Beitragpath Anat. 1931;86:440–443
  2. Biorck G, Axen O, Thorson A. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J. Jul 1952;44(1):143–148
  3. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. Dec 2003;22(4):517–530
  4. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. May 2005;128(6):1717–1751
  5. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988 Feb;77(2):264–269
  6. Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. Sep 1985;79(3):339–354
  7. Moyssakis IE, Rallidis LS, Guida GF, Nihoyannopoulos PI. Incidence and evolution of carcinoid syndrome in the heart. J Heart Valve Dis. Nov 1997;6(6):625–630
  8. Howard RJ, Drobac M, Rider WD, et al. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation. Nov 1982;66(5):1059–1065
  9. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. Apr 1993;87(4):1188–1196
  10. Lundin L, Landelius J, Andren B, Oberg K. Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. Br Heart J. Sep 1990;64(3):190–194
  11. Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol. 1993;32(2):197–201
  12. Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol. Feb 1 1989;63(5):347–352
  13. Moller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. Nov 22 2005;112(21):3320–3327
  14. Artaza A, Beiner JA, Gonzalez M, et al. Carcinoid heart disease: report of a case secondary to a pure carcinoid tumour of the ovary. Eur Heart J. Sep 1985;6(9):800–805
  15. Bernheim AM, Connolly HM, Pellikka PA. Carcinoid heart disease in patients without hepatic metastases. Am J Cardiol. Jan 15 2007;99(2):292–294
  16. Greminger P, Hess OM, Muller AE, et al. Bronchial neuroendocrine (carcinoid) tumor causing unilateral left-sided carcinoid heart disease. Klin Wochenschr. Feb 6 1991;69(3):128–133
  17. Shehata BM, Thomas JE, Doudenko-Rufforny I. Metastatic carcinoid to the conducting system—is it a rare or merely unrecognized manifestation of carcinoid cardiopathy?. Arch Pathol Lab Med. Dec 2002;126(12):1538–1540
  18. Moller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. Mar 13 2003;348(11):1005–1015
  19. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. Apr 1 2003;97(7):1609–1615
  20. Cosh J, Cates JE, Pugh DW. Carcinoid heart disease. Br Heart J. Jul 1959;21:369–380
  21. Oates JA, Melmon K, Sjoerdsma A, et al. Release of a kinin peptide in the carcinoid syndrome. Lancet. Mar 7 1964;1:514–517
  22. Ferrans VJ, Roberts WC. The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol. Jul 1976;7(4):387–409
  23. Nilsson J, von Euler AM, Dalsgaard CJ. Stimulation of connective tissue cell growth by substance P and substance K. Nature. May 2–8 1985;315(6014):61–63
  24. Waldenstrom J, Ljungberg E. Studies on the functional circulatory influence from metastasizing carcinoid (argentaffine, enterochromaffine) tumours and their possible relation to enteramine production. I. Symptoms of cardinoidosis. Acta Med Scand. Nov 10 1955;152(4):293–309
  25. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis. Nov 2001;10(6):827–831
  26. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis. Mar 2000;9(2):256–260discussion 60-1
  27. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. Jan 2000;57(1):75–81
  28. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med. Aug 28 1997;337(9):581–588
  29. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. Dec 5 2000;102(23):2836–2841
  30. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. Sep 2007;6(9):826–829
  31. Roth BL. Drugs and valvular heart disease. N Engl J Med. Jan 4 2007;356(1):6–9
  32. Gustafsson BI, Tommeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation. Mar 29 2005;111(12):1517–1522
  33. Hauso O, Gustafsson BI, Loennechen JP, et al. Long-term serotonin effects in the rat are prevented by terguride. Regul Pept. Oct 4 2007;143(1–3):39–46
  34. Elangbam CS, Wehe JG, Barton JC, et al. Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague–Dawley rats with spontaneous mitral valvulopathy—a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats?. Exp Toxicol Pathol. Nov 2006;58(2–3):89–99
  35. Kidd M, Modlin IM, Eick GN, et al. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol. Jan 2007;292(1):G191–200
  36. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. Mar 25 1986;261(9):4337–4345
  37. Waltenberger J, Lundin L, Oberg K, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. Jan 1993;142(1):71–78
  38. Jian B, Xu J, Connolly J, et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol. Dec 2002;161(6):2111–2121
  39. Walker GA, Masters KS, Shah DN, et al. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res. Aug 6 2004;95(3):253–260
  40. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol. Dec 2004;99(12):2466–2478
  41. Kidd M, Modlin IM, Shapiro MD, et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol. Oct 21 2007;13(39):5208–5216
  42. Sakai D, Murakami M, Kawazoe K, Tsutsumi Y. Ileal carcinoid tumor complicating carcinoid heart disease and secondary retroperitoneal fibrosis. Pathol Int. May 2000;50(5):404–411
  43. Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. Feb 2002;77(2):139–147
  44. Hoffmann J, Grimm W, Menz V, et al. Heart rate variability in carcinoid heart disease. Am J Cardiol. Jan 1 1999;83(1):128–131A9
  45. Langer C, Piper C, Vogt J, et al. Atrial fibrillation in carcinoid heart disease : the role of Serotonin. A review of the literature. Clin Res Cardiol. Feb 2007;96(2):114–118
  46. McGuire MR, Pugh DM, Dunn MI. Carcinoid heart disease. Restrictive cardiomyopathy as a late complication. J Kans Med Soc. Dec 1978;79(12):661–6625
  47. Blick DR, Zoghbi WA, Lawrie GM, Verani MS. Carcinoid heart disease presenting as right-to-left shunt and congestive heart failure: successful surgical treatment. Am Heart J. Jan 1988;115(1 Pt 1):201–203
  48. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. Mar 1 2005;89(3):151–160
  49. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. Jun 1 2004;90(11):2073–2079
  50. Bastarrika G, Cao MG, Cano D, et al. Magnetic resonance imaging diagnosis of carcinoid heart disease. J Comput Assist Tomogr. Nov–Dec 2005;29(6):756–759
  51. Veitch AM, Morgan-Hughes GJ, Roobottom CA. Carcinoid heart disease as shown by 64-slice CT coronary angiography. Eur Heart J. Oct 2006;27(19):2271
  52. Mansencal N, Mitry E, Forissier JF, et al. Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J. May 2006;151(5):1129;e1-6
  53. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. May 2006;4(5):526–547
  54. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J. Oct 1997;134(4):693–702
  55. Denney WD, Kemp WE, Anthony LB, et al. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol. Oct 1998;32(4):1017–1022
  56. Onate A, Alcibar J, Inguanzo R, et al. Balloon dilation of tricuspid and pulmonary valves in carcinoid heart disease. Texas Heart Inst J. 1993;20(2):115–119
  57. Grant SC, Scarffe JH, Levy RD, Brooks NH. Failure of balloon dilatation of the pulmonary valve in carcinoid pulmonary stenosis. Br Heart J. Jun 1992;67(6):450–453
  58. Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. Feb 1995;25(2):410–416
  59. Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. Mar 1 1995;75(7):485–488
  60. Wright PW, Mulder DG. Carcinoid heart disease. Report of a case treated by open heart surgery. Am J Cardiol. Dec 1963;12:864–868
  61. Ridker PM, Chertow GM, Karlson EW, et al. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J. Jun 1991;121(6 Pt 1):1835–1838
  62. Ohri SK, Schofield JB, Hodgson H, et al. Carcinoid heart disease: early failure of an allograft valve replacement. Ann Thorac Surg. Oct 1994;58(4):1161–1163
  63. Knott-Craig CJ, Schaff HV, Mullany CJ, et al. Carcinoid disease of the heart. Surgical management of ten patients. J Thorac Cardiovasc Surg. Aug 1992;104(2):475–481
  64. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. Jun 1999;18(2):133–141
  65. Makridis C, Ekbom A, Bring J, et al. Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery. Dec 1997;122(6):1075–1082

PII: S0167-5273(08)00436-1

doi: 10.1016/j.ijcard.2008.02.019

International Journal of Cardiology
Volume 129, Issue 3 , Pages 318-324 , 13 October 2008

Article Tools

* Image Usage & Resolution